TY - JOUR
KW - Adult
KW - Buprenorphine/administration & dosage
KW - Female
KW - Hepatitis Antibodies/blood
KW - Hepatitis C/complications/drug therapy/epidemiology/virology
KW - Humans
KW - Male
KW - Middle Aged
KW - New York City/epidemiology
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/complications/rehabilitation
KW - Patient Compliance
KW - Treatment Outcome
KW - buprenorphine
KW - Cascade of care
KW - Hepatitis C
KW - medication assisted treatment
KW - opioid use disorder
AU - B. L. Norton
AU - A. Beitin
AU - M. Glenn
AU - J. DeLuca
AU - A. H. Litwin
AU - C. O. Cunningham
A1 - 
AD - Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States. Electronic address: bnorton@montefiore.org.; Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States.; Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States.; Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States.; Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States.; Montefiore Medical Center, Albert Einstein College of Medicine, Division of General Internal Medicine, Bronx, NY, United States.
BT - Journal of substance abuse treatment
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CY - United States
DO - 10.1016/j.jsat.2017.01.015
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
PB - Elsevier Inc
PP - United States
PY - 2017
SN - 1873-6483; 0740-5472
SP - 38
EP - 42
EP - 
T1 - Retention in buprenorphine treatment is associated with improved HCV care outcomes
T2 - Journal of substance abuse treatment
TI - Retention in buprenorphine treatment is associated with improved HCV care outcomes
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 28237052
U3 - 10.1016/j.jsat.2017.01.015
VL - 75
VO - 1873-6483; 0740-5472
Y1 - 2017
Y2 - Apr
ER -